Evidence map›Paper›PMID 28855212›Full record

ArticleCancer research2017

Sensitivity to

Eunjee Lee, Margaret Pain, Huaien Wang, Jacob A Herman, Chad M Toledo, Jennifer G DeLuca, Raymund L Yong, Patrick Paddison, Jun Zhu

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. NAR cancer · 2024
    Article
  3. Article
  4. Review
  5. Hyper-active RAS/MAPK introduces cancer-specific mitotic vulnerabilities.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Identification ofTranslational cancer research · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Eunjee LeeDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Margaret PainDepartment of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Huaien WangDepartment of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Jacob A HermanDepartment of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, Colorado.
Chad M ToledoHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Jennifer G DeLucaDepartment of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, Colorado.
Raymund L YongDepartment of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Patrick PaddisonHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Jun ZhuDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York. jun.zhu@mssm.edu.
Icahn School of Medicine at Mount Sinai · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAColorado State University · US

Funding

Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's DiseaseU01AG046170 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EHRLICH, MICHELLE E, GANDY, SAMUEL E. · 2013 to 2022
$26.0M
MYC-dependent loss of splicing fidelity in Glioblastoma multiformeR01CA190957 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PADDISON, PATRICK · 2015 to 2019
$2.2M
Transforming Genomics with 5 PB Big Omics Data Engine Cray CS300-AC SupercomputerS10OD018522 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2014 to 2014
$1.9M
Developing methods for curating multi-omics dataU01HG008451 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ZHU, JUN · 2015 to 2017
$1.5M
Evolution of cancer-specific molecular requirements for glioblastoma multiforme (R21CA170722 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PADDISON, PATRICK, ZHU, JUN · 2012 to 2013
$418k
NCI NIH HHS R01 CA190957NCI NIH HHS R21 CA170722NHGRI NIH HHS U01 HG008451NIA NIH HHS U01 AG046170NIH HHS S10 OD018522
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) remains a mainly incurable disease in desperate need of more effective treatments. In this study, we develop evidence that the mitotic spindle checkpoint molecule

Indexed as

Antineoplastic Agents, PhytogenicBiomarkers, TumorBrain NeoplasmsCamptothecinCell Cycle ProteinsCell Line, TumorEtoposideGene Expression ProfilingGlioblastomaHumansIrinotecanProtein Serine-Threonine KinasesRNA, MessengerAntineoplastic Agents, PhytogenicBiomarkers, TumorBUB1B protein, humanCamptothecinCell Cycle ProteinsEtoposideIrinotecanProtein Serine-Threonine KinasesRNA, Messenger

Identifiers

PMID28855212
PMCPMC5645262
OpenAlexW2752643813

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.